Phosphonopeptides based on aminomethylphosphonic acid as the C-terminal residue linked to L-amino acids possessed antibacterial activity in vitro and in vivo. Analogs in this series were generally less potent than corresponding compounds based on L-1-aminoethylphosphonic acid such as alafosfalin (L-alanyl-L-1-aminoethylphosphonic acid). Significant differences in antibacterial spectra were observed. The mechanism of action involved active transport of the peptide mimetics into the bacterial cells, followed by intracellular release of high concentrations of aminomethylphosphonic acid which inhibited bacterial cell wall biosynthesis. Aminomethylphosphonic acid behaved as a mimetic of both D-and L-alanine and inhibited D-Ala-D-Ala synthetase (EC 6.3.2.4.), alanine racemase (EC 5.1.1.1.), and UDP-N-acetylmuramyl-L-alanine synthetase (EC 6.3.2.8.). The minimal inhibitory concentration of L-norvalyl-aminomethylphosphonic acid was essentially unaffected by the presence of D-alanine, whereas the activity of the corresponding L-norvalyl derivative of L-1-aminoethylphosphonic acid was markedly decreased. Substantial differences in the inhibitory and lytic activity of the Lnorvalyl derivatives of aminomethylphosphonic and L-1-aminoethylphosphonic acids were also observed when these agents were combined with other inhibitors of bacterial cell wall biosynthesis.
Previous papers have described results of investigations on the antibacterial properties of phosphonopeptides (1) (2) (3) (4) (5) (6) (7) . Alafosfalin [L-alanyl-L-1-aminoethylphosphonic atid; L-Ala-L-Ala(P)] has been selected for clinical studies in humans. Other related compounds incorporating L-Ala(P) are of interest for particular applications in therapy.
In these studies, phosphonopeptides with alternative aminoalkylphosphonic acid residues were investigated. Phosphonopeptides incorporating aminomethylphosphonic acid, Gly(P), were the only compounds with levels of antibacterial activity comparable with those of the LAla(P) series. In this paper, we investigated phosphonopeptides in which various L-amino acids are combined with Gly(P).
MATERIALS AND METHODS
Amino add and peptide nimetics. The term amino acid mimetic as used in this paper refers to synthetic variants of conventional a-amino acids with the carboxyl group replaced by alternative acidic functions, usually the phosphoryl (P [O] [OH]2) group. Peptide mimetics incorporate residues of these amino acid mimetics. (All amino acids and amino acid mimetics described below are of the L-series unless otherwise indicated, and L iS therefore generally omitted in the abbreviations.) Chemicals. The phosphonopeptides described in this report were synthesized by the methods described previously (7) .
Chemical characteristics of the new compounds described in this paper are as shown in Table 1 . The symbols for higher unbranched amino acids (2-aminooctanoic acid [Aoc] aConfirmed by C, H, and N analysis, which were in all cases within 0.5% of the theoretical value.
b Specific optical rotation (in degrees of rotation); 0.5% in H20 unless otherwise stated.
c NA, Not applicable. d C = 1% in H20. I C = 1% in acetic acid. f C = 0.5% in 1 N HCI. 9 C = 0.5% in 0.1 N NaOH.
mum inhibitory concentrations (MICs) were determined by an agar incorporation method as described previously (7) , using final concentrations of antimicrobial agents ranging from 0.007 to 128 ,ug/ml. The defined susceptibility medium, free from antagonists to small peptide mimetics, reported previously (2), or an improvement of this medium (5) Transport and metabolsm of phosphonopepddes. Early-to midexponential-phase cultures of Escherichia coli were harvested, washed, and suspended in 10 ml of defined medium or Davis minimal medium (9) at 37'C at a cell density of 1.5 x 108 to 3 x 108 bacteria per ml. After a 10-min preincubation to allow cells to recover, 100 FaM Ala414C]Gly(P) (7.6 mCi/mmol) was added to the 10-ml cultures. Samples (1 ml) were taken at intervals and centrifuged, and the cells were suspended in 0.1 ml of water. The cell contents were extracted from the 0.1-ml samples by heating them to 100°C for 5 min. After centrifugation in an Eppendorf microcentrifuge, 10Ojml samples of the supernatants were applied to Whatman no. 1 filter paper (presoaked in 4%6 formic acid, pH 1.8), and Ala-Gly(P) was separated from its metabolites by high-voltage electrophoresis (100 V/cm) as described previously for alafosfalin (6) .
Total uptake of phosphonopeptides was determined by using 5 ml-cultures as described above. Samples 572 ATHERTON ET AL.
(0.5 ml) were taken at intervals, and the cells were harvested by rapid filtration by using Whatman GF/C filter disks. The filters were washed twice with 5 ml of 0.8% (wt/vol) NaCl at 20°C and dried, and the radioactivity was determined by liquid scintillation counting.
Transport studies were also carried out in the presence of D-alanine or peptides. Intracellular concentrations of phosphonopeptide related material were calculated by using a cell volume of 2.7 ,ul/mg (dry weight) of cells (16) . Incorporation of labeled precursor into whole-cel peptidoglycan and protein fractons. Cell wall and protein biosynthesis were measured in E. coli by following the incorporation of [G-2,6-meso-3H]diaminopimelic acid and L-[U-14C]valine into trichloroacetic acid-insoluble material as previously described (6) . Peptidoglycan and protein biosynthesis in Staphylococcus aureus were both followed by measuring incorporation of L-[4,5-3H]lysine and employing a selective pronase method to distinguish the fractions (8) .
Isolation and characterization of cell wail precursor UDP-muramyl peptides in S. aureus. The contents of cells treated with Ala-Gly(P) were released by heating at 100°C for 5 min, the precipitated material was removed by centrifugation, and the N-acetylhexosamine content was determined (6) . Nucleotide muropeptide precursors were separated from cell extracts by charcoal adsorption or ion-exchange chromatography. After elution, they were characterized by paper chromatography, electrophoresis, and amino acid analysis as previously described (6) .
The standard muropeptide precursors uridine diphosphate-N-acetylmuramic acid (UDP-NAMA), UDP-NAMA-Ala, and UDP-NAMA-tri-and pentapeptides were obtained as previously described (12) , and they were chemically identified by amino acid and hexosamine analysis and by Fourier-transform nuclear magnetic resonance.
Preparation and assay of other cel wail enzymes. DAla-D-Ala synthetase (EC 6.3.2.4) (Streptococcusfaecalis), UDP-NAMA-L-Ala synthetase (EC 6.3.2.8) (Staphylococcus aureus), and alanine racemase (EC 5.1.1.1) (E. colt) were prepared and assayed by previously described methods (13, 14) . 
RESULTS
Antibacterial actity ofX-Gly(P) phosphonodipeptides. Structure-activity relationships in the X-Gly(P) series were generally parallel to the corresponding X-Ala(P) compounds described previously (1, 5, 7) . Where the N-terminal residue was a natural L-amino acid or glycine, the dipeptides containing Arg, Leu, or Met again showed the greatest antibacterial activity, whereas Gly-Gly(P) and Pro-Gly(P), which are particularly stable to peptide hydrolases (unpublished observations), were inactive at 128 ,ug/ml against all organisms tested (Table 2) .
A series of X-Gly(P) compounds containing straight-chain aliphatic amino acids (X = L-H2NCH[(CH2)nH]-CO [n = 0 to 8]) were highly potent, as for the corresponding X-Ala(P) case (5), with optimal activity again falling between n = 3 and n = 6, i.e., Nva-Gly(P) and Aoc-Gly(P) ( Table 3 ). In contrast to the X-Ala(P) series, all compounds, including Nva-Gly(P), were inactive against Pseudomonas aeruginosa at 128 ,ug/ ml. A series of sulfur-containing compounds of the general formula X-Gly(P) in which X = L-
H2NCH[-CH2S(CH2)mH]-CO (m = 1 to 5) had
no significant advantages in antibacterial activity in comparison to corresponding X-Gly(P) compounds containing straight-chain aliphatic ammo acids.
Arg-Gly(P) and Nva-Gly(P) have been investigated for activity against clinical bacterial isolates and compared with alafosfalin and the corresponding Ala(P) analogs (Table 4 ). In general, the Gly(P)-containing dipeptides were less potent against most gram-negative bacteria. However, there were some significant differences in antibacterial spectra. Arg-Gly(P) was more effective than Arg-Ala(P) against Proteus isolates and against staphylococci. Nva-Gly(P) was more active than Nva-Ala(P) against staphylococci (Table 4) . These in vitro results were reflected in vivo, using a mouse septicemia model (Table 5 ). Curative doses of Arg-Gly(P) and Nva-Gly(P) for infections with Proteus mirabilis 502075 and Staphylococcus aureus 561057 were lower than in the case of Ala(P) analogs.
Transport of phosphonodipeptides containing Gly(P) by E. coli. Transport of Nva-Gly(P) into E. coli NCIB 8879 occurred rapidly with the intracellular concentration of phosphonopeptide-derived material typically reaching 200 mM (Fig. 1) . The larger part of this material was present as Gly(P). Ala-Gly(P) was transported at a significantly lower rate than Nva-Gly(P), whereas uptake of Gly(P) was almost undetect- able. After a 15-min incubation of E. coli with Nva-Gly(P), a decrease in turbidity occurred because of cell lysis, and radioactivity was released into the medium (Fig. 1) . This rapid lytic phase was suppressed in the presence of Dalanine. Transport of Nva-Gly(P) into E. coli was inhibited by all L-di-and L-tripeptides but not by L-tetrapeptides, as previously observed for alafosfalin (6) .
Effect of Ala-Gly(P) and Gly(P) on bacterial ceil wail biosynthesis. Cell wall biosynthesis as measured by incorporation of precursor amino acids was inhibited in E. coli and in Staphylococcus aureus by Ala-Gly(P). In response to 100 ,ug of Ala-Gly(P) per ml, Staphylococcus aureus R2192 produced 6.6 nmol of hexosamine-positive material per ml of culture. Three putative intermediates were detected with electrophoretic mobilities that were consistent with the production of UDP-NAMA, UDP-NAMA-Ala, and muramyl tripeptide.
Electrophoresis of the cell contents of E. coli NCIB 8879 after Ala-[14C]Gly(P) uptake revealed an additional metabolite tentatively identified as UDP-NAMA-Gly(P), possessing similar characteristics to metabolite M, which is formed in the presence of alafosfalin (6) .
When the action of active metabolite Gly(P) on isolated enzymes was investigated, it was shown to be a competitive inhibitor of alanine racemase and UDP-NAMA-L-Ala synthetase, as was L-Ala(P) released from alafosfalin (Table 6 ). In addition, Gly(P) also inhibited D-Ala-D-Ala synthetase. This was presumably due to the absence of a chiral center on the carbon atom next to phosphorus which allows the Gly(P) to act as a mimetic of both L-and D-alanine.
Effect of D-alanine on the antibacterial activity of Nva-Gly(P) and Nva-Ala(P). Alafosfalin induces an early lytic response in E. coli that is abolished by including D-alanine in the medium (6) . A similar effect of D-alanine on lysis was observed when E. coli cells were treated with either Nva-GIy(P) or Nva-Ala(P) for 40 min (Fig.  1) . However, D-alanine had very little effect on the antibacterial activity of Nva-Gly(P) measured in MIC determinations after 16 h of treatment. This was in contrast to a substantial reduction in the antibacterial activity of NvaAla(P) in the presence of D-alanine with most of to the organisms examined (Table 7) .
Synergy between Nva-Gly(P) and ceil wail biosynthesis Inhibitors. Nva-Gly(P) showed antibacterial synergy with cephalexin ( Fig. 2A) and with D-cycloserine (Fig. 2B) in Staphylococcus aureus strains; this effect was more pronounced when Nva-Ala(P) replaced Nva-Gly(P) in the combinations.
Synergy was also observed in Proteus mirabilis by investigating lytic effects with other agents known to inhibit the early stages of bacterial cell wall biosynthesis. Nva-Gly(P) caused enhanced lysis of Proteus mirabilis when combined with fosfomycin, whereas this did not occur with Nva-Ala(P) (Fig. 3A) . In contrast, when Dcycloserine was substituted for fosfomycin, lysis was more pronounced in combination with Nvaynergy be-Ala(P) than with Nva-Gly(P) (Fig. 3B) staphylococci, were notable. The mechanism of action of the Gly(P) dipeptides involved active transport, intracellular hydrolysis, and inhibition of bacterial cell wall biosynthesis and in several respects resembled that of the Ala(P) series. However, a difference in the response of gram-negative bacteria sensitive to Nva-Ala(P) and Nva-Gly(P) was noted. Whereas the initial lysis reaction to these agents was similar and was antagonized by D-Ala in both cases, the antimicrobial activity of Nva-Gly(P) alone was essentially unaffected by D-Ala upon longer term incubation. It is possible that the early phase of lysis, which is common to both aminoalkylphosphonic acids, is due to the effect that they have in inhibiting alanine racemase, whereas the later phases are more influenced by the specific ability of Gly(P) to inhibit D-Ala-D-Ala synthetase. The results of experiments using combinations of Nva-Gly(P) with D-cycloserine are also consistent with this explanation. When D-cycloserine, acting as a potent inhibitor of D-Ala-D-Ala synthetase, was combined with Nva-Ala(P), cell lysis was substantially enhanced. These lytic effects were not observed when Nva-Gly(P) replaced Nva-Ala(P) in the combination.
In summary, the mechanism of action of dipeptides in the Gly(P) series differs from that of analogs based on Ala(P) in that the aminomethylphosphonic acid moiety can inhibit enzymes which utilize both D-and L-amino acids as substrates.
